Olivier Christophe

Documents

Publications

Fitusiran treatment modulates the ratio between alpha‐ and beta‐antithrombin isoforms

Geneviève Mccluskey , Hortense Maynadié , Delphine Borgel , Laurent Frenzel , Annie Harroche et al.

HemaSphere, 2026, 10 (5), pp.e70376. ⟨10.1002/hem3.70376⟩

Article dans une revue hal-05667331v1

A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options

Geneviève Mccluskey , Marco Heestermans , Ivan Peyron , Eloise Pascal , Marie Clavel et al.

Haematologica, In press, ⟨10.3324/haematol.2024.286076⟩

Article dans une revue (data paper) hal-04871911v1

A bispecific nanobody for the treatment of von Willebrand disease type 1

Ivan Peyron , Caterina Casari , Geneviève Mccluskey , Stéphanie Roullet , Vincent Licari et al.

Blood, 2025, ⟨10.1182/blood.2025029401⟩

Article dans une revue hal-05263486v1

A consistent clinical factor VIII-equivalence is unlikely to exist for non-factor therapies in hemophilic mice

Thibaud Sefiane , Geneviève Mccluskey , Marie Clavel , Hortense Maynadié , Ivan Peyron et al.

Haematologia, In press, ⟨10.3324/haematol.2024.286982⟩

Article dans une revue hal-05051687v1

Clinical, Phenotypic and Genotypic Characteristics of Von Willebrand Disease in Afro‐Caribbeans: Results From a Study in Martinique Island, French West Indies

Marie‐daniéla Dubois , Olivier Nicolas Pierre-Louis , Serge Pierre-Louis , Pierre Boisseau , Cécile Denis et al.

Haemophilia, 2025, 31 (3), pp.458-476. ⟨10.1111/hae.70003⟩

Article dans une revue hal-05045740v1

Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody

Vincent Muczynski , Olivier Christophe , Lewis Tanner , Charlotte Vayssiere , Alice Guérin et al.

Blood, 2025, ⟨10.1182/blood.2024027709⟩

Article dans une revue hal-05299843v1

Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice

Antoine Babuty , Javier Muñoz-Garcia , Olivier Christophe , Laurie Fradet , Manon Taupin et al.

Bone Research, In press

Article dans une revue hal-05319155v1

Von Willebrand factor: how unique structural adaptations support and coordinate its complex function

Peter J. Lenting , Cécile Denis , Olivier Christophe

Blood, 2024, 144 (21), pp.2174-2184. ⟨10.1182/blood.2023023277⟩

Article dans une revue hal-04817254v1

Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

Thibaud Sefiane , Hortense Maynadié , Carmen Escurola Ettingshausen , Vincent Muczynski , Xavier Heiligenstein et al.

Haematologica, 2024, ⟨10.3324/haematol.2023.284142⟩

Article dans une revue hal-04449388v1

Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab

Sénadé Atsou , Célia Schellenberg , Jeremy Lagrange , Patrick Lacolley , Peter Lenting et al.

Journal of Thrombosis and Haemostasis, 2024, 22 (1), pp.112-125. ⟨10.1016/j.jtha.2023.09.017⟩

Article dans une revue hal-04449373v1

Fitusiran reduces bleeding in factor X–deficient mice

Sebastien Verhenne , Geneviève Mccluskey , Hortense Maynadié , Frédéric Adam , Caterina Casari et al.

Blood, 2024, 144 (2), pp.227-236. ⟨10.1182/blood.2023023404⟩

Article dans une revue hal-04654300v1

Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension

Alejandra Reyes-Ruiz , Sandrine Delignat , Aishwarya Sudam Bhale , Victoria Daventure , Robin Lacombe et al.

Haematologica, 2024, 110, pp.1523-1535. ⟨10.3324/haematol.2024.286536⟩

Article dans une revue hal-05361041v1

Transplacental delivery of therapeutic proteins by engineered IgG: a step towards perinatal replacement therapy

Angelina Mimoun , Melissa Bou Jaoudeh , Sandrine Delignat , Victoria Daventure , Alejandra Reyes Ruiz et al.

Journal of Thrombosis and Haemostasis, In press, ⟨10.1016/j.jtha.2023.05.021⟩

Article dans une revue hal-04117814v1

Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor

Alexis Texier , Peter Lenting , Cécile Denis , Stéphanie Roullet , Olivier Christophe

Research and Practice in Thrombosis and Haemostasis, 2023, HITH, 7 (7), pp.102204. ⟨10.1016/j.rpth.2023.102204⟩

Article dans une revue (data paper) hal-04449394v1

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

Claire Kizlik-Masson , Ivan Peyron , Stéphane Gangnard , Gaelle Le Goff , Solen Lenoir et al.

Blood, 2023, 141 (12), pp.1457-1468. ⟨10.1182/blood.2022017569⟩

Article dans une revue inserm-04258451v1

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab

Melissa Bou-Jaoudeh , Angelina Mimoun , Sandrine Delignat , Ivan Peyron , Ladislas Capdevila et al.

Journal of Thrombosis and Haemostasis, 2023, 21 (10), pp.2776-2783. ⟨10.1016/j.jtha.2023.06.038⟩

Article dans une revue hal-04217783v1

Toll-like receptor 4 and macrophage scavenger receptor 1 crosstalk regulates phagocytosis of a fungal pathogen

Chinaemerem Onyishi , Guillaume Desanti , Alex Wilkinson , Samuel Lara-Reyna , Eva-Maria Frickel et al.

Nature Communications, 2023, 14 (1), pp.4895. ⟨10.1038/s41467-023-40635-w⟩

Article dans une revue hal-04449439v1

Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

Guillaume Postic , Jean Solarz , Cécile Loubière , Janany Kandiah , Jaysen Sawmynaden et al.

Journal of Cellular and Molecular Medicine, 2023, 27 (15), pp.228-2238. ⟨10.1111/jcmm.17817⟩

Article dans une revue anses-04164790v1

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

Elena Barbon , Charlotte Kawecki , Solenne Marmier , Aboud Sakkal , Fanny Collaud et al.

Gene Therapy, 2023, 30 (3-4), pp.245-254. ⟨10.1038/s41434-020-00218-6⟩

Article dans une revue hal-04455812v1

Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in Von Willebrand disease murine models

Stéphanie Roullet , Norman Luc , Julie Rayes , Jean Solarz , Dante Disharoon et al.

Blood, 2023, 141 (23), pp.2891-2900. ⟨10.1182/blood.2022018956⟩

Article dans une revue inserm-04066466v1

In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model

Eléanor Luce , Clara Steichen , Mickaël Allouche , Antonietta Messina , Jean-Marie Heslan et al.

Hepatology, 2022, 75 (4), pp.866-880. ⟨10.1002/hep.32211⟩

Article dans une revue inserm-04251849v1

The VWF/LRP4/aVb3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells

Jérémy Lagrange , Morel Worou , Jean-Baptiste Michel , Alexandre Raoul , Mélusine Didelot et al.

Cardiovascular Research, 2022, 118 (2), pp.622-637. ⟨10.1093/cvr/cvab042⟩

Article dans une revue hal-03267669v1

Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization

Marie‐daniéla Dubois , Ivan Peyron , Olivier‐nicolas Pierre-Louis , Serge Pierre-Louis , Johalène Rabout et al.

Research and Practice in Thrombosis and Haemostasis, 2022, 6 (4), pp.e12737. ⟨10.1002/rth2.12737⟩

Article dans une revue hal-04354187v1

Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S

Josepha Sedzro , Frédéric Adam , Claire Auditeau , Elsa Bianchini , Allan de Carvalho et al.

Journal of Thrombosis and Haemostasis, 2022, 20 (7), pp.1653-1664. ⟨10.1111/jth.15736⟩

Article dans une revue inserm-04455219v1

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

Elena Barbon , Charlotte Kawecki , Solenne Marmier , Aboud Sakkal , Fanny Collaud et al.

Gene Therapy, 2021, 30 (3-4), pp.245-254. ⟨10.1038/s41434-020-00218-6⟩

Article dans une revue (data paper) hal-04324328v1

A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient

Marie Daniela Dubois , Serge Pierre-Louis , Johalène Rabout , Cécile Denis , Olivier Christophe et al.

TH Open : Companion Journal To Thrombosis and Haemostasis, 2020, 04 (04), pp.e318-e321. ⟨10.1055/s-0040-1718703⟩

Article dans une revue hal-04683162v1

Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors

Elena Barbon , Gabriel Ayme , Amel Mohamadi , Jean-François Ottavi , Charlotte Kawecki et al.

EMBO Molecular Medicine, 2020, 12 (4), pp.e11298. ⟨10.15252/emmm.201911298⟩

Article dans une revue inserm-02551254v1

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Stephen Ferrière , Ivan Peyron , Olivier D. Christophe , Charlotte Kawecki , Caterina Casari et al.

Blood, 2020, 136 (6), pp.740-748. ⟨10.1182/blood.2019004334⟩

Article dans une revue inserm-02916896v1

Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation

Charlotte Kawecki , Karen Aymonnier , Stephen Ferrière , Laurence Venisse , Véronique Arocas et al.

Journal of Thrombosis and Haemostasis, 2020, 18, pp.2155-2168. ⟨10.1111/jth.14940⟩

Article dans une revue inserm-02934843v1

In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A

Matteo Campioni , Paulette Legendre , Cécile Loubiere , Barbara Lunghi , Mirko Pinotti et al.

Journal of Thrombosis and Haemostasis, 2020, Online ahead of print. ⟨10.1111/jth.15131⟩

Article dans une revue (data paper) inserm-02983110v1

Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications

Ivan Peyron , Claire Kizlik‐masson , Marie‐daniéla Dubois , Sénadé Atsou , Stephen Ferrière et al.

Research and Practice in Thrombosis and Haemostasis, 2020, 4 (7), pp.1087-1110. ⟨10.1002/rth2.12420⟩

Article dans une revue hal-03116405v1

A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient

Marie Daniela Dubois , Serge Pierre-Louis , Johalène Rabout , Cécile Denis , Olivier Christophe et al.

TH Open : Companion Journal To Thrombosis and Haemostasis, 2020, 04 (04), pp.e318-e321. ⟨10.1055/s-0040-1718703⟩

Article dans une revue hal-03121861v1

Removal of Mannose-Ending Glycan at Asn 2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells

Sandrine Delignat , Julie Rayes , Suryasarathi Dasgupta , Bagirath Gangadharan , Cecile V. Denis et al.

Frontiers in Immunology, 2020, 11, pp.393. ⟨10.3389/fimmu.2020.00393⟩

Article dans une revue inserm-02553450v1

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII- encoding mRNA

Jules Russick , Sandrine Delignat , Peter Milanov , Olivier D. Christophe , Gábor Boros et al.

Haematologica, 2019, 105 (4), pp.1129-1137. ⟨10.3324/haematol.2018.210583⟩

Article dans une revue hal-02328193v1

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A

Vincent Muczynski , Sebastien Verhenne , Caterina Casari , Ghislaine Chérel , Laurence Panicot-Dubois et al.

Thrombosis and Haemostasis, 2019, 119 (12), pp.1981-1993. ⟨10.1055/s-0039-1697662⟩

Article dans une revue hal-02570572v1

A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor

Stephen Ferrière , Charlotte Kawecki , Jean‐françois Ottavi , Cécile Denis , Alexandre Kauskot et al.

Journal of Thrombosis and Haemostasis, 2019, 17 (12), pp.2035-2046. ⟨10.1111/jth.14615⟩

Article dans une revue hal-04456634v1

Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia

Karen Aymonnier , Charlotte Kawecki , Laurence Venisse , Yacine Boulaftali , Olivier D Christophe et al.

Blood, 2019, 134 (19), pp.1632-1644. ⟨10.1182/blood.2019000281⟩

Article dans une revue inserm-03116956v1

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor

Nikolett Wohner , Vincent Muczynski , Amel Mohamadi , Paulette Legendre , Valérie Proulle et al.

Haematologica, 2018, 103 (4), pp.728-737. ⟨10.3324/haematol.2017.175216⟩

Article dans une revue hal-04456818v1

Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability

Frédéric Adam , Alexandre Kauskot , Mathieu Kurowska , Nicolas Goudin , Isabelle Munoz et al.

Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38 (5), pp.1037-1051. ⟨10.1161/ATVBAHA.117.310373⟩

Article dans une revue inserm-02440288v1

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

Florence Boisgérault , Amine Meliani , Romain Hardet , Solenne Marmier , Fanny Collaud et al.

Nature Communications, 2018, 9 (1), pp.4098. ⟨10.1038/s41467-018-06621-3⟩

Article dans une revue hal-02177709v1

A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation

Vincent Muczynski , Caterina Casari , François Moreau , Gabriel Ayme , Charlotte Kawecki et al.

Blood, 2018, 132 (11), pp.1193-1197. ⟨10.1182/blood-2018-01-829523⟩

Article dans une revue hal-03209466v1

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor

Nikolett Wohner , Vincent Muczynski , Amel Mohamadi , Paulette Legendre , Valérie Proulle et al.

Haematologica, 2018, 103 (4), pp.728-737. ⟨10.3324/haematol.2017.175216⟩

Article dans une revue pasteur-03209471v1

A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation

Vincent Muczynski , Caterina Casari , François Moreau , Gabriel Aymé , Charlotte Kawecki et al.

Blood, 2018, 132 (11), pp.1193-1197. ⟨10.1182/blood-2018-01-829523⟩

Article dans une revue (data paper) hal-04456589v1

Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets

Caterina Casari , David Paul , Sophie Susen , Cécile Lavenu-Bombled , Annie Harroche et al.

Blood Advances, 2018, 2 (12), pp.1417-1428. ⟨10.1182/bloodadvances.2017014290⟩

Article dans une revue hal-04376230v1

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions

Vincent Muczynski , Gabriel Aymé , Véronique Regnault , Marc Vasse , Delphine Borgel et al.

Blood, 2017, 129 (17), pp.2443-2454. ⟨10.1182/blood-2016-06-724351⟩

Article dans une revue hal-03567147v1

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors

Amine Meliani , Florence Boisgérault , Zachary Fitzpatrick , Solenne Marmier , Christian Leborgne et al.

Blood Advances, 2017, 1 (23), pp.2019-2031. ⟨10.1182/bloodadvances.2017010181⟩

Article dans une revue hal-02377508v1

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation—Brief Report

Gabriel Ayme , Frédéric Adam , Paulette Legendre , Amine Bazaa , Valérie Proulle et al.

Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37 (9), pp.1736-1740. ⟨10.1161/ATVBAHA.117.309319⟩

Article dans une revue pasteur-03209478v1

Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis

Abdel-Majid Khatib , Rachid Lahlil , Martin Hagedorn , Claudine Delomenie , Olivier Christophe et al.

Oncotarget, 2016, 7 (11), pp.12102-12120. ⟨10.18632/oncotarget.7728⟩

Article dans une revue hal-03519971v1

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B

Alexandre Kauskot , Sonia Poirault-Chassac , Frédéric Adam , Vincent Muczynski , Gabriel Ayme et al.

JCI Insight, 2016, 1 (16), pp.e88643. ⟨10.1172/jci.insight.88643⟩

Article dans une revue hal-03209475v1

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Bharath Wootla , Olivier D. Christophe , Ankit Mahendra , Jordan Dimitrov , Yohann Repessé et al.

Blood, 2011, 117 (7), pp.2257-2264. ⟨10.1182/blood-2010-07-296103⟩

Article dans une revue inserm-02455570v1

Clearance of von Willebrand factor.

Cécile V. Denis , Olivier D. Christophe , Beatrijs D. Oortwijn , Peter J. Lenting

Thrombosis and Haemostasis, 2008, 99 (2), pp.271-8

Article dans une revue (article de synthèse) inserm-00260376v1

L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand

Alexis Texier , Peter J. Lenting , Cécile Denis , Stéphanie Roullet , Olivier Christophe

44ème congrès de la Société Française d'Hématologie, Société Française d'Hématologie, Mar 2024, Paris, France. pp.P327, Abstract 18-03

Communication dans un congrès inserm-04541054v1

A consistent in vivo factor VIII-equivalence is unlikely to exist for non-factor therapies

Hortense Maynadié , Thibaud Sefiane , Genevieve Mccluskey , Marie Clavel , Ivan Peyron et al.

Congrès Français d'Hémostase, Société Française de Thrombose et d'Hémostase, Sep 2024, Lille, France

Communication dans un congrès hal-04701045v1

L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand

Alexis Texier , Peter J. Lenting , Cécile Denis , Stéphanie Roullet , Olivier Christophe

44e congrès annuel de la Société Française d’Hématologie, Société Française d’Hématologie, Mar 2024, Paris, France. p 327, abstract 18-03

Communication dans un congrès hal-04654288v1

Fitusiran displays efficient pro-hemostatic activity in a mouse model of inducible factor X-deficiency

Genevieve Mccluskey , Sebastien Verhenne , Hortense Maynadié , Cécile Denis , Olivier Christophe et al.

World Federation of Hemophilia, World Federation of Hemophilia, Apr 2024, Madrid, Spain

Communication dans un congrès hal-04654270v1

Fitusiran-treatment modulates the ratio between alpha- and beta-antithrombin isoforms

Geneviève Mccluskey , Hortense Maynadié , Caterina Casari , Delphine Borgel , Laurent Frenzel et al.

Congrès Français d'Hémostase, Société Française de Thrombose et d'Hémostase, Sep 2024, Lille, France

Communication dans un congrès hal-04701035v1

A single-domain antibody enhancing protein S activity reduces vaso-occlusion in two murine models of sickle cell disease

Claire Auditeau , Thiago Maciel , Josepha Sedzro , Camille Roussel , Aurélie Fricot-Monsinjon et al.

European Congress on Thrombosis and Haemostasis, Sep 2023, Valence (Espagne), Spain

Communication dans un congrès hal-04501174v1

Llama-derived single-domain antibodies blocking tissue factor pathway inhibitor and increasing thrombin generation in FVIII- and FX-deficient plasma

Francois Saller , Ivan Peyron , Andrea Ruty , Saenjamsai P , Claire Auditeau et al.

European Congress on Thrombosis and Haemostasis, Sep 2023, Valence (Espagne), Spain

Communication dans un congrès hal-04501177v1

A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a

Vincent Muczynski , Angel Smith , Thibaud Sefiane , Olivier Christophe , Peter J. Lenting et al.

ASH abstracts, Nov 2022, San Diego (CA), United States. pp.677-678, ⟨10.1182/blood-2022-169482⟩

Communication dans un congrès hal-04501469v1

Transplacental Delivery of Maternal FVIII for Induction of FVIII-specific Immune Tolerance

Angelina Mimoun , Melissa Bou Jaoudeh , Ivan Peyron , Victoria Daventure , Sandrine Delignat et al.

Hybrid Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2021, Philadelphia (Pennsylvania), United States. pp.Abstract OC 14.1

Communication dans un congrès hal-04501088v1

Antithrombotic Potential of a Single-domain Antibody Enhancing the Anticoagulant Activity of Protein S

Josepha Sedzro , Frédéric Adam , Allan De Carvalho , Elsa P Bianchini , Ivan Peyron et al.

Communication dans un congrès hal-04501112v1

Caractérisation d’une nanobody qui potentialize l’activité cofacteur de la protéine C active de la protéine S

Sedzro Jc , Francois Saller , Frédéric Adam , De Carvalho , Sophie Gandrille et al.

40ème congrès de la Société Française d’Hématologie, Société Française d’Hématologie, Sep 2020, Paris, France. pp.Page 39, Abstract 04-01

Communication dans un congrès hal-04501074v1

p.(Pro2145Thrfs5) et p.(Cys2216Phefs9), deux Nouvelles mutations identifiées dans le domaine D4 du facteur von Willebrand chez des patientes d’origine afro-caribéenne

Marie Daniela Dubois , Serge Pierre-Louis , Johalène Rabout , Cécile Denis , Olivier Christophe et al.

40ème congrès de la Société Française d’Hématologie, Société Française d’Hématologie, Sep 2020, Paris, France. p 50, Abstract 05-07

Communication dans un congrès hal-04501081v1

A inducible mouse model of Factor X deficiency to test novel FX therapeutics

Sebastien Verhenne , Loubiere C , Cécile Denis , Peter J. Lenting , Olivier Christophe

XXVIIth Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia. pp.Abstract OC 28.4

Communication dans un congrès hal-04499851v1

Von Willebrand factor induces human vascular smooth muscle cells proliferation through low density lipoprotein-related receptor 4 and alphavbeta3 integrin

Morel Worou , Melusine Didelot , Vincent Muczynski , Raoul A , Paulette Legendre et al.

XXVIIth Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia

Communication dans un congrès hal-04498513v1

Targeting Protease Nexin-1, a natural anticoagulant to control bleeding in hemophilia A

Karen Aymonnier , Charlotte Kawecki , Laurence Venisse , Emmanuelle de Raucourt , Olivier Christophe et al.

XXVIIth Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia. pp.Abstract OC 75.3

Communication dans un congrès hal-04498448v1

Développement d’un modèle de souris avec un déficit inductible en facteur X

Sebastien Verhenne , Loubière Cécile , Elena Barbon , F Mingozzi , Cécile Denis et al.

39th Congress of the Société Française d’Hématologie, Société Française d’Hématologie, Mar 2019, Paris, France. pp.Abstract 12-29

Communication dans un congrès hal-04498403v1

The potential use of nanobodies delivered via AAV vectors in the treatment of hemophilia

Elena Barbon , Gabriel Ayme , Amel Mohamadi , Cécile Denis , Olivier Christophe et al.

21st Annual Meeting of the American Society of Gene and Cell Therapy, American Society of Gene and Cell Therapy, May 2018, CHICAGO, United States

Communication dans un congrès hal-04457494v1

La Protéase Nexine-1, un inhibiteur physiologique de la thrombine, cible potentielle dans le traitement de l’hémophilie.

Karen Aymonnier , Charlotte Kawecki , Laurence Venisse , Emmanuelle de Raucourt , Olivier Christophe et al.

38th Congress of the Société Française d’Hématologie, Société Française d’Hématologie, Mar 2018, PARIS, France. p 133, Abstract 12-59

Communication dans un congrès hal-04457483v1

Targeting Protease Nexin-1, a natural anticoagulant to control bleeding in hemophilia A

Karen Aymonnier , Charlotte Kawecki , Laurence Venisse , Emmanuelle de Raucourt , Olivier Christophe et al.

2nd European Congress on Thrombosis and Haemostasis, Oct 2018, Marseille, France

Communication dans un congrès hal-04457505v1

Protein engineering in FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate

Tihomir Dodev , Petya Kalcheva , Azadeh Kia , Samantha Correia , Caterina Casari et al.

Protein Engineering Summit PEGS, Aug 2020, Boston - online, United States

Poster de conférence hal-04461544v1

Transplacental delivery of maternal factor VIII for induction of immune tolerance to therapeutic factor VIII

Angelina Mimoun , Melissa Bou Jaoudeh , Ivan Peyron , Daventure V , Sandrine Delignat et al.

Virtual Congress of the International Society on Thrombosis and Haemostasis, Jul 2020, Milan (Virtual), Italy. Res. Pract. Thromb. Haemost, 4 (Suppl. 1), pp.Abstract PB0177, 2020

Poster de conférence hal-04501045v1

Development of single domain antibodies targeting protease nexin-1 as a strategy for hemophilia treatment

Charlotte Kawecki , Karen Aymonnier , Laurence Venisse , Véronique Arocas , Olivier Christophe et al.

XXVIIth Congress of the International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia. Res. Pract. Thromb. Haemost, 3 (Suppl. 1), pp.Abstract PB0316, 2019

Poster de conférence hal-04499858v1

Modulation of the platelet count by Romiplostim and inhibitors of LIM kinase in genetically-engineered von Willebrand disease type 2B mice: in vivo evaluation of haemostatic efficiency.

Mathilde Cheptou , Frédéric Adam , Olivier Christophe , Peter Lenting , Cécile Denis et al.

ECTH, 2018, Oct 2018, Marseille, France

Poster de conférence hal-04455308v1

Design and Characterization of FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate

Azadeh Kia , Fabrizio Comper , Samantha Correia , Caterina Casari , Segen Negash et al.

61 ASH Annual Meeting, Blood, 134 (Supplement_1), pp.4638-4638, 2019, ⟨10.1182/blood-2019-128490⟩

Proceedings/Recueil des communications hal-04461585v1

Thrombin-mediated activation of factor VIII is insufficient to produce all necessary cofactor activity in vivo

Charlotte Kawecki , Ivan Peyron , Amine Bazaa , Vincent Muczynski , Stephen Ferrière et al.

Congress of the International Society of Thrombosis and Haemostasis, Research and Practice in Thrombosis and Haemostasis, 3, pp.1-891, 2019, ⟨10.1002/rth2.12229⟩

Proceedings/Recueil des communications hal-04461945v1

Chargement...

Olivier Christophe

Publications

Publications

Fitusiran treatment modulates the ratio between alpha‐ and beta‐antithrombin isoforms

A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options

A bispecific nanobody for the treatment of von Willebrand disease type 1

A consistent clinical factor VIII-equivalence is unlikely to exist for non-factor therapies in hemophilic mice

Clinical, Phenotypic and Genotypic Characteristics of Von Willebrand Disease in Afro‐Caribbeans: Results From a Study in Martinique Island, French West Indies

Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody

Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice

Von Willebrand factor: how unique structural adaptations support and coordinate its complex function

Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab

Fitusiran reduces bleeding in factor X–deficient mice

Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension

Transplacental delivery of therapeutic proteins by engineered IgG: a step towards perinatal replacement therapy

Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab

Toll-like receptor 4 and macrophage scavenger receptor 1 crosstalk regulates phagocytosis of a fungal pathogen

Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in Von Willebrand disease murine models

In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model

The VWF/LRP4/aVb3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells

Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization

Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient

Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation

In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A

Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications

A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient

Removal of Mannose-Ending Glycan at Asn 2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII- encoding mRNA

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A

A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor

Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor

Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor

A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation

Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation—Brief Report

Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Clearance of von Willebrand factor.

L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand

A consistent in vivo factor VIII-equivalence is unlikely to exist for non-factor therapies

L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand

Fitusiran displays efficient pro-hemostatic activity in a mouse model of inducible factor X-deficiency

Fitusiran-treatment modulates the ratio between alpha- and beta-antithrombin isoforms

A single-domain antibody enhancing protein S activity reduces vaso-occlusion in two murine models of sickle cell disease

Llama-derived single-domain antibodies blocking tissue factor pathway inhibitor and increasing thrombin generation in FVIII- and FX-deficient plasma

A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a

Transplacental Delivery of Maternal FVIII for Induction of FVIII-specific Immune Tolerance

Antithrombotic Potential of a Single-domain Antibody Enhancing the Anticoagulant Activity of Protein S

Caractérisation d’une nanobody qui potentialize l’activité cofacteur de la protéine C active de la protéine S

p.(Pro2145Thrfs*5) et p.(Cys2216Phefs*9), deux Nouvelles mutations identifiées dans le domaine D4 du facteur von Willebrand chez des patientes d’origine afro-caribéenne

A inducible mouse model of Factor X deficiency to test novel FX therapeutics

Von Willebrand factor induces human vascular smooth muscle cells proliferation through low density lipoprotein-related receptor 4 and alphavbeta3 integrin

Targeting Protease Nexin-1, a natural anticoagulant to control bleeding in hemophilia A

Développement d’un modèle de souris avec un déficit inductible en facteur X

The potential use of nanobodies delivered via AAV vectors in the treatment of hemophilia

La Protéase Nexine-1, un inhibiteur physiologique de la thrombine, cible potentielle dans le traitement de l’hémophilie.

Targeting Protease Nexin-1, a natural anticoagulant to control bleeding in hemophilia A

Protein engineering in FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate

Transplacental delivery of maternal factor VIII for induction of immune tolerance to therapeutic factor VIII

Development of single domain antibodies targeting protease nexin-1 as a strategy for hemophilia treatment

Modulation of the platelet count by Romiplostim and inhibitors of LIM kinase in genetically-engineered von Willebrand disease type 2B mice: in vivo evaluation of haemostatic efficiency.

Design and Characterization of FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate

Thrombin-mediated activation of factor VIII is insufficient to produce all necessary cofactor activity in vivo

p.(Pro2145Thrfs5) et p.(Cys2216Phefs9), deux Nouvelles mutations identifiées dans le domaine D4 du facteur von Willebrand chez des patientes d’origine afro-caribéenne